IonQ (SR) will host a conference call at 4:30 PM ET on November 5, 2026, to discuss Q3 26 earnings results.
To access the live webcast, log on to https://investors.ionq.com/events-and-presentations/default.aspx
To listen to the call, dial 1-888-349-0106 (US) or 1-412-902-0131 (International).
For a replay call, dial 1-855-669-9658 (US) or 1-412-317-0088 (International).Access code :7647193.
For comments and feedback contact: [email protected]
Business News
November 03, 2026 10:34 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.